1. Home
  2. ALLO vs LAND Comparison

ALLO vs LAND Comparison

Compare ALLO & LAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • LAND
  • Stock Information
  • Founded
  • ALLO 2017
  • LAND 1997
  • Country
  • ALLO United States
  • LAND United States
  • Employees
  • ALLO N/A
  • LAND N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • LAND Real Estate Investment Trusts
  • Sector
  • ALLO Health Care
  • LAND Real Estate
  • Exchange
  • ALLO Nasdaq
  • LAND Nasdaq
  • Market Cap
  • ALLO 438.2M
  • LAND 477.4M
  • IPO Year
  • ALLO 2018
  • LAND 2013
  • Fundamental
  • Price
  • ALLO $1.82
  • LAND $10.77
  • Analyst Decision
  • ALLO Strong Buy
  • LAND Strong Buy
  • Analyst Count
  • ALLO 10
  • LAND 4
  • Target Price
  • ALLO $10.06
  • LAND $17.33
  • AVG Volume (30 Days)
  • ALLO 3.1M
  • LAND 337.7K
  • Earning Date
  • ALLO 03-13-2025
  • LAND 02-19-2025
  • Dividend Yield
  • ALLO N/A
  • LAND 5.24%
  • EPS Growth
  • ALLO N/A
  • LAND N/A
  • EPS
  • ALLO N/A
  • LAND N/A
  • Revenue
  • ALLO $43,000.00
  • LAND $88,454,000.00
  • Revenue This Year
  • ALLO N/A
  • LAND N/A
  • Revenue Next Year
  • ALLO N/A
  • LAND $4.57
  • P/E Ratio
  • ALLO N/A
  • LAND N/A
  • Revenue Growth
  • ALLO 26.47
  • LAND N/A
  • 52 Week Low
  • ALLO $1.78
  • LAND $10.27
  • 52 Week High
  • ALLO $5.78
  • LAND $15.36
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 36.69
  • LAND 44.33
  • Support Level
  • ALLO $2.11
  • LAND $10.57
  • Resistance Level
  • ALLO $2.10
  • LAND $11.07
  • Average True Range (ATR)
  • ALLO 0.17
  • LAND 0.23
  • MACD
  • ALLO -0.02
  • LAND 0.07
  • Stochastic Oscillator
  • ALLO 5.69
  • LAND 62.50

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About LAND Gladstone Land Corporation

Gladstone Land Corp is an externally-managed, agricultural REIT. It is mainly in the business of owning and leasing farmland. It manages operations in one reporting segment. It is focused on the ownership of high-quality farms and farm-related properties that are leased on a triple-net basis to tenants with a strong operating history and deep farming resources. The farmland is predominantly concentrated in locations where farmers are able to grow either fresh produce annual row crops (e.g., certain berries and vegetables), which are typically planted and harvested annually, or certain permanent crops (e.g., almonds, blueberries, pistachios, and wine grapes). To a much lesser extent, it also own farms that grow certain commodity crops (e.g., corn and beans).

Share on Social Networks: